EPISODE · May 1, 2025 · 18 MIN
Treatment Options for HER2 Positive Biliary Tract Cancers
from Oncology Brothers: Practice-Changing Cancer Discussions · host Oncology Brothers
Welcome to another episode of the Oncology Brothers podcast! In this episode, Drs. Rohit and Rahul Gosain, both practicing community medical oncologists, continue their discussion on HER2-positive biliary tract cancer. They are joined by Dr. Shubham Pant from MD Anderson, who shares his expertise on this rapidly evolving field.In this episode, we cover:• The importance of HER2 testing in biliary tract cancers, including intrahepatic and extrahepatic cholangiocarcinomas and gallbladder cancers.• Who should be tested for HER2 positivity and how to classify HER2-positive disease.• The role of next-generation sequencing (NGS) and immunohistochemistry (IHC) in determining HER2 status.• Current treatment options for HER2-positive biliary tract cancer, including the latest clinical trials and approved therapies like trastuzumab deruxtecan and zanidatamab.• The significance of patient-centered decision-making and managing side effects associated with these treatments.• Insights into the potential for brain metastases in biliary tract cancer and the importance of ongoing surveillance.Join us as we delve into the latest data and strategies for managing HER2-positive biliary tract cancer, and stay tuned for our next episode where we will discuss side effects and management of these therapies.Accreditation/Credit DesignationPhysicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Acknowledgment of Commercial SupportThis activity is supported by an educational grant from Jazz Pharmaceuticals, Inc.Link to gain CME credits from this activity:https://www.gotoper.com/courses/from-bench-to-bedside-paradigm-shifts-in-her2-metastatic-btc-treatmentFollow us on social media:• X/Twitter: https://twitter.com/oncbrothers• Instagram: https://www.instagram.com/oncbrothers• Website: https://oncbrothers.com/Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!
What this episode covers
Welcome to another episode of the Oncology Brothers podcast! In this episode, Drs. Rohit and Rahul Gosain, both practicing community medical oncologists, continue their discussion on HER2-positive biliary tract cancer. They are joined by Dr. Shubham Pant from MD Anderson, who shares his expertise on this rapidly evolving field.In this episode, we cover:• The importance of HER2 testing in biliary tract cancers, including intrahepatic and extrahepatic cholangiocarcinomas and gallbladder cancers.• Who should be tested for HER2 positivity and how to classify HER2-positive disease.• The role of next-generation sequencing (NGS) and immunohistochemistry (IHC) in determining HER2 status.• Current treatment options for HER2-positive biliary tract cancer, including the latest clinical trials and approved therapies like trastuzumab deruxtecan and zanidatamab.• The significance of patient-centered decision-making and managing side effects associated with these treatments.• Insights into the potential for brain metastases in biliary tract cancer and the importance of ongoing surveillance.Join us as we delve into the latest data and strategies for managing HER2-positive biliary tract cancer, and stay tuned for our next episode where we will discuss side effects and management of these therapies.Accreditation/Credit DesignationPhysicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Acknowledgment of Commercial SupportThis activity is supported by an educational grant from Jazz Pharmaceuticals, Inc.Link to gain CME credits from this activity:https://www.gotoper.com/courses/from-bench-to-bedside-paradigm-shifts-in-her2-metastatic-btc-treatmentFollow us on social media:• X/Twitter: https://twitter.com/oncbrothers• Instagram: https://www.instagram.com/oncbrothers• Website: https://oncbrothers.com/Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!
NOW PLAYING
Treatment Options for HER2 Positive Biliary Tract Cancers
No transcript for this episode yet
Similar Episodes
Mar 31, 2026 ·54m
Mar 27, 2026 ·14m
Mar 24, 2026 ·42m
Mar 20, 2026 ·42m
Mar 17, 2026 ·41m
Mar 13, 2026 ·44m